Open AccessHepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective
Author(s) -
Karina Salvatierra,
Sabrina Fareleski,
Alicia Forcada,
F. Xavier LópezLabrador
Publication year - 2013
Publication title -
world journal of virology
Language(s) - English
Resource type - Journals
ISSN - 2220-3249
DOI - 10.5501/wjv.v2.i1.6
Subject(s) - telaprevir , boceprevir , medicine , ribavirin , hepatitis c virus , virology , pegylated interferon , virus , drug resistance , biology , microbiology and biotechnology
Until very recently, treatment for chronic hepatitis C virus (HCV) infection has been based on the combination of two non-viral specific drugs: pegylated interferon-α and ribavirin, which is effective in, overall, about 40%-50% of cases. To improve the response to treatment, novel drugs have been designed to specifically block viral proteins. Multiple compounds are under development, and the approval for clinical use of the first of such direct-acting antivirals in 2011 (Telaprevir and Boceprevir), represents a milestone in HCV treatment. HCV therapeutics is entering a new expanding era, and a highly-effective cure is envisioned for the first time since the discovery of the virus in 1989. However, any antiviral treatment may be limited by the capacity of the virus to overcome the selective pressure of new drugs, generating antiviral resistance. Here, we try to provide a basic overview of new treatments, HCV resistance to new antivirals and some considerations derived from a Public Health perspective, using HCV resistance to protease and polymerase inhibitors as examples.